Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to -$1.1 billion.

  • Gsk's Cash from Financing Activities rose 6645.11% to -$1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$5.0 billion, marking a year-over-year increase of 4015.58%. This contributed to the annual value of -$4.9 billion for FY2025, which is 1955.93% up from last year.
  • Latest data reveals that Gsk reported Cash from Financing Activities of -$1.1 billion as of Q4 2025, which was up 6645.11% from -$1.8 billion recorded in Q3 2025.
  • In the past 5 years, Gsk's Cash from Financing Activities registered a high of $10.7 billion during Q1 2022, and its lowest value of -$6.2 billion during Q3 2022.
  • For the 5-year period, Gsk's Cash from Financing Activities averaged around $14.3 million, with its median value being -$1.2 billion (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 66384.97% in 2022, then tumbled by 525401.22% in 2024.
  • Gsk's Cash from Financing Activities (Quarter) stood at $4.3 billion in 2021, then dropped by 5.07% to $4.1 billion in 2022, then tumbled by 108.71% to -$356.2 million in 2023, then plummeted by 852.69% to -$3.4 billion in 2024, then soared by 66.45% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q4 2025, -$1.8 billion for Q3 2025, and -$3.2 billion during Q2 2025.